诺和龙联合二甲双胍治疗初发2型糖尿病患者疗效观察.docVIP

诺和龙联合二甲双胍治疗初发2型糖尿病患者疗效观察 　　[摘要] 目的 评价诺和龙联合二甲双胍治疗初发2型糖尿病的临床疗效。 方法 将收治入院的初发82例患者分为两组，单药治疗组44例（A组）给予诺和龙单药，联合用药组38例（B组）给予诺和龙和二甲双胍联合治疗，于治疗1个月及3个月时，评价及比较两组血糖控制情况，并记录服药期间的副作用。 结果 治疗1个月时，两组的空腹血糖及餐后2 h血糖水平均较治疗前明显降低，且联合用药组的餐后2 h血糖水平显著低于单用诺和龙组（P＜0.05）。治疗3个月时，两组FPG、2 h PG、及HbA1c水平均有明显差异，联合用药组显著低于诺和龙单药组，差异有统计学意义（P＜0.05）。3个月时联合用药组的甘油三酯水平明显低于治疗前，但与单药治疗组比较，差异无统计学意义（P＞0.05）。两组患者服药期间无明显的不良反应，对诺和龙有较好的耐受性，无严重的低血糖情况发生。 结论 诺和龙可有效控制初发2型糖尿病的血糖水平，与二甲双胍合用时可更好地降低餐后高血糖，并可改善患者对治疗的敏感性，且无严重低血糖等不良反应。 　　[关键词] 诺和龙；二甲双胍；2型糖尿病；临床疗效 　　[中图分类号] R587.1 [文献标识码] B [文章编号] 1673-9701（2012）01-051-03 　　 　　The clinical efficacy of Novolon（repaglinide）combined with metformin on the patients with primary type 2 diabetes mellitus 　　ZHENG Yuanjun 　　Geriatrics Deptarmet of Hangzhou TCM Hospital in Zhejiang Province，Hangzhou 310007，China 　　 　　[Abstract] Objective To evaluate the clinical efficacy of Novolon (repaglinide) with metformin on the patients with primary Type 2 diabetes mellitus. Methods All of 82 patients with primary Type 2 diabetes mellitus were divided into two groups：repaglinide group (A group，44) and repaglinide + metformin group (B group，38) whose therapy course were 3 months. We compared the control of blood glucose between the two groups at 1 month and 3 months and the adverse effect was also recorded. Results At 1 month，fasting plasma glucose (FPG) and 2 h postprandial plasma glucose (2 h PG) decreased in both of the two groups than pretherapy. And，2 h PG of the B group was lower than A group (P＜0.05) . At 3 months，FPG、2 h PG and HbA1c of the B group were significantly lower than that of the A group. Triglyceride was decreasing over 3 months，but it was no significance compared with the A group (P＞0.05). The patients in both groups were well in tolerance with Novolon and there were no obviously adverse effect such as severe hypoglycaemia. Conclusion Novolon could effectively control the glucose in the patients with primary T2DM. Repaglinide + metformin decreased the postprandial plasma gluc